Kala Pharmaceuticals Acquires Combangio, Adding KPI-012 to Ophthalmic Pipeline

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

Takeda Pharmaceutical Acquires PvP Biologics

February 26, 2020

Biotechnology

Takeda Pharmaceutical Company Limited exercised its option to acquire PvP Biologics, Inc. following positive Phase 1 proof-of-mechanism results for TAK-062 (Kuma062), an oral engineered glutenase for celiac disease. The deal includes a pre-negotiated upfront payment and up to $330 million in development and regulatory milestones and brings TAK-062 and TAK-101 into Takeda's gastroenterology pipeline.

Asahi Kasei Medical Acquires Bionova Scientific

April 14, 2022

Biotechnology

Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.

Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business

February 23, 2026

Biotechnology

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.

Bausch + Lomb Affiliate Acquires Whitecap Biosciences

January 13, 2025

Pharmaceuticals

An affiliate of Bausch + Lomb Corporation has acquired clinical-stage Whitecap Biosciences, LLC, which is developing two ophthalmic therapies (WB007 and WB006) for glaucoma and geographic atrophy. The deal strengthens Bausch + Lomb's clinical-stage pipeline — Whitecap completed a Phase 2 study for WB007 and plans additional trials for both indications.